This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Why Seeking Alpha's Larry Smith Is Wrong Again About Northwest Bio.

Stocks in this article: NWBO

BOSTON ( TheStreet) -- Seeking Alpha contributor Larry "Smith on Stocks" Smith has written six articles on Northwest Biotherapeutics (NWBO) in the past 10 months, all of which have promoted the blockbuster potential of the company's cancer immunotherapy. Smith is long Northwest Biotherapeutics. In the same time period, I wrote a single column expressing an opinion that investors should avoid Northwest Bio, mainly because the company exaggerates and misleads investors about the data backing its cancer therapy. I have no financial interest in Northwest Bio.

In his latest article, Smith accuses me of being unfair to Northwest Bio. He believes his prodigious output on the stock represents "a balanced perspective."


Smith writes, "Mr. Feuerstein implies elsewhere in his blog that Northwest was attempting to portray this as a randomized trial comparing DCVax-L to a control group of patients and that this was deceitful." DCVax is the name given to Northwest Bio's cancer therapy targeted at glioblastoma (GBM), a form of brain tumor.

That's incorrect. What I said quite clearly was Northwest Bio was misleading investors by comparing overall survival data from its small-single arm study of DCVax in 20 GBM patients with survival data obtained from a separate group of 119 GBM patients who were not participants in Northwest Bio clinical trials.

Why is comparing sets of data from two different groups of patients misleading? I'll let Smith explain. Here's what he wrote about the phase I trials of DCVax in an April 26, 2012 Seeking Alpha article It's the only sensible thing he's ever written about the company and its lead drug:

The Phase I trials of DCVax-L enrolled a small number of patients in non-randomized trials performed at one clinical site. Such trials are subject to investigator bias, albeit inadvertent, as investigators have a tendency to select for younger, healthier patients. They are reluctant to enroll older, sicker patients with poor prognosis who might die regardless of treatment. No one wants to see a new drug be judged ineffective because it is given to patients for whom there is very little hope for survival. In Phase II and III clinical trials, however, such patients do find their way in. There is an axiom in cancer drug development that Phase III results are never as good as Phase II results and Phase II results are never as good as Phase I results. Comparing results from different trials is also viewed suspiciously because protocols and the characteristics of the patient populations can vary widely, especially when comparing small Phase I to large Phase III trials.

Amen, Larry!

Smith offers good advice then immediately ignores it. The claims made by Northwest Bio about the DCVax survival data from a tiny number of patients should be met with extreme skepticism and distrust by investors. Instead, Smith accepts them unconditionally -- a classic and common mistake made by retail biotech investors. Institutional investors are wiser and more skeptical, which is why Northwest Bio's institutional investor ownership is de minimus.

Smith writes, "NWBO Northwest Bio was not able to finance through the capital markets until very recently because of the weak financial position of the company and the skepticism of the investment community about immunotherapy... Ms. Powers, certain non-traditional investors and Cognate were the only sources of capital available."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs